A recent survey revealed Canadians back the regulation of psilocybin, with over 80% approving of the psychedelic compound’s use in palliative care.
As the public have thrown their support behind psilocybin, and research endorses its therapeutic potential, how many more milestones need to be passed on the road to regulation?
Read More
The country’s first psychedelic-assisted therapy clinic plans to open in Autumn, providing ketamine treatments.
Read More
The company closed an overnight public offering of approximately 10 million shares, which raised C$34 million.
Read More
Join us at our next PSYCH Investor Summit, 7 October 2021
Register for ticketsMAPS awarded US$12m research grant from state of Michigan.
Johnson & Johnson denied data protection rights for Spravato in Canada.
Revive Therapeutics to conduct clinical trials to treat methamphetamine use disorder.
Psygen raises C$5m to complete manufacturing facility.
Wesana Health conducts studies to treat traumatic brain injury with psilocybin.
Compass Pathways shares COMP360 clinical trial update.
Incannex Healthcare submits proposals for Phase II clinical trials.
Core One Labs to design psychedelic medicine trials for stroke and depression.
Silo Wellness enters the UK through distributor agreement.
PharmaDrug partners with Terasaki Institute to develop drug delivery technology.
Ketamine One integrates virtual reality technology into psychedelic therapy.
Mindset Pharma releases early results from tryptamine analogue research.
Tryp Therapeutics partners with Calvert Labs to study psilocybin derivatives.
Levitee Labs appoints Dr Fady Hannah-Shmouni as Chief Medical and Scientific Officer.
With a nudge from AI, ketamine emerges as a potential rare-disease treatment.
Wuhan General Group publishes research paper on psilocybin’s anti-inflammatory properties.
Psychedelic medicine co-administration with lithium linked to seizures.
Study examines challenges of integrating psilocybin therapy with palliative care.
Researchers concerned about whitewashing of psychedelic research.
In Canada, end-of-life therapy may be the path to legal psilocybin.
Grand Rapids is getting close to decriminalising psychedelic plants and fungi.
Oregon decriminalised all drugs to stop overdoses. Will it work?
Psychedelic decriminalisation only scratches the surface.